1
项与 GSK-2654911A 相关的临床试验An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of different formulations of a two-dose primary series and booster vaccination of monovalent Influenza H9N2 vaccine manufactured in Quebec, Canada with and without adjuvant, in adults 18 to 64 years of age.
100 项与 GSK-2654911A 相关的临床结果
100 项与 GSK-2654911A 相关的转化医学
100 项与 GSK-2654911A 相关的专利(医药)
100 项与 GSK-2654911A 相关的药物交易